Multiple Myeloma
2,358
338
543
1,088
Key Insights
Highlights
Success Rate
78% trial completion
Published Results
555 trials with published results (24%)
Research Maturity
1088 completed trials (46% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
13.0%
306 terminated out of 2358 trials
78.0%
-8.5% vs benchmark
12%
278 trials in Phase 3/4
51%
555 of 1088 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1088 completed trials
Clinical Trials (2358)
Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells
Serum Soluble BCMA as a Non-Invasive Marker in Multiple Myeloma
Natural Killer Cells and Bortezomib to Treat Cancer
Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM)
A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
Preliminary Assessment of [18F]BL40 in PET/CT Scans
Effects of Controlled Breathing Added to Therapeutic Exercise in Multiple Myeloma
Exercise Phenotyping Prior to Chemotherapy in Newly Diagnosed Multiple Myeloma (MM-Exercise)
Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders
Integrative Therapies in Multiple Myeloma
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas